In 1970, Fox et al. noted that Allo, a xanthine oxidase (XO) inhibitor widely used clinically in the treatment of gout, leads to the depletion of phosphoribosyl pyrophosphate (PRPP) in patients [7]. The gene discussed is XDH; the disease is gout.